Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway

被引:56
|
作者
Haspot, Fabienne [1 ]
Fehr, Thomas [1 ]
Gibbons, Carrie [1 ]
Zhao, Guiling [1 ]
Hogan, Timothy [1 ]
Honjo, Tasuku [2 ]
Freeman, Gordon J. [3 ]
Sykes, Megan [1 ]
机构
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA 02129 USA
[2] Kyoto Univ Yoshida Konoe, Fac Med, Dept Med Chem, Kyoto, Japan
[3] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med, Boston, MA 02129 USA
关键词
D O I
10.1182/blood-2007-12-127449
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although interaction between programmed death-1 (PID-11) and the ligand PD-L1 has been shown to mediate CD8 cell exhaustion in the setting of chronic infection or the absence of CD4 help, a role for this pathway in attenuating early alloreactive CD8 cell responses has not been identified. We demonstrate that the PD-1/PD-L1 pathway is needed to rapidly tolerize alloreactive CD8 cells in a model that requires Cl cells and culminates in CD8 cell deletion. This protocol involves allogeneic bone marrow transplantation (BMT) following conditioning with low-dose total body irradiation and anti-CD154 antibody. Tolerized donor-reactive T-cell receptor transgenic CD8 cells are shown to be in an abortive activation state prior to their deletion, showing early and prolonged expression of activation markers (compared with rejecting CD8 cells) while being functionally silenced by day 4 after transplantation. Although both tolerized and rejecting alloreactive Cl cells up-regulate PD-1, CD8 cell tolerance is dependent on the PD-1/PD-L1 pathway. In contrast, CD4 cells are tolerized independently of this pathway following BMT with anti-CD154. These studies demonstrate a dichotomy between the requirements for CD4 and CD8 tolerance and identify a role for PD-1 in the rapid tolerization of an alloreactive T-cell population via a deletional mechanism.
引用
收藏
页码:2149 / 2155
页数:7
相关论文
共 50 条
  • [1] PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus
    Marchevsky, Alberto M.
    Watts, Ann E.
    [J]. HUMAN PATHOLOGY, 2017, 60 : 16 - 23
  • [2] PD-L1, PD-1, CD4 and CD8 Expression in Neoplastic and Non-Neoplastic Thymus
    Walts, Ann E.
    Marchevsky, Alberto M.
    [J]. LABORATORY INVESTIGATION, 2016, 96 : 486A - 486A
  • [3] PD-L1, PD-1, CD4 and CD8 Expression in Neoplastic and Non-Neoplastic Thymus
    Walts, Ann E.
    Marchevsky, Alberto M.
    [J]. MODERN PATHOLOGY, 2016, 29 : 486A - 486A
  • [4] Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma
    Nowicki, Theodore S.
    Akiyama, Ryan
    Huang, Rong Rong
    Shintaku, I. Peter
    Wang, Xiaoyan
    Tumeh, Paul C.
    Singh, Arun
    Chmielowski, Bartosz
    Denny, Christopher
    Federman, Noah
    Ribas, Antoni
    [J]. CANCER IMMUNOLOGY RESEARCH, 2017, 5 (02) : 118 - 126
  • [5] PD-1 and PD-L1 Expression in Peripheral CD4/CD8+ T Cells Is Restored in the Partial Remission Phase in Type 1 Diabetes
    Li, Xia
    Zhong, Ting
    Tang, Rong
    Wu, Chao
    Xie, Yuting
    Liu, Fang
    Zhou, Zhiguang
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (06): : 1947 - 1956
  • [6] Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
    Escors, David
    Bocanegra, Ana
    Chocarro, Luisa
    Blanco, Ester
    Pineiro-Hermida, Sergio
    Garnica, Maider
    Fernandez-Rubio, Leticia
    Vera, Ruth
    Arasanz, Hugo
    Kochan, Grazyna
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (21)
  • [7] Expression of PD-1/PD-L1 axis and CD4/CD8 ratio in mediastinal lymph nodes of human and experimental lung fibrosis
    Karampitsakos, T.
    Galaris, A.
    Chrysikos, S.
    Papaioannou, O.
    Vamvakaris, I.
    Anagnostopoulos, A.
    Stratakos, G.
    Katsaras, M.
    Sampsonas, F.
    Dimakou, K.
    Manali, E.
    Papiris, S.
    Bouros, D.
    Bakakos, P.
    Aidinis, V.
    Tzouvelekis, A.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [8] PD-1-expressing B cells suppress CD4+ and CD8+ T cells via PD-1/PD-L1-dependent pathway
    Wang, Xufu
    Wang, Guoqiang
    Wang, Zenghua
    Liu, Bin
    Han, Na
    Li, Jiao
    Lu, Chenghui
    Liu, Xinfeng
    Zhang, Qin
    Yang, Qingbo
    Wang, Guoming
    [J]. MOLECULAR IMMUNOLOGY, 2019, 109 : 20 - 26
  • [9] Association of tumor and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with response to nivolumab treatment in NSCLC patients
    Sahba, S.
    Niemeijer, A-L.
    De langen, J.
    Thunnissen, E.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [10] CD57+CD8+T cells and response to PD-1/PD-L1 blockade in patients with NSCLC
    Zhou, Jianya
    Sun, Wenjia
    Zeng, Xun
    Zheng, Jing
    Qu, Jingjing
    Jiang, Nan
    Zhou, Jianying
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)